AZD8701 + durvalumab

AZD8701 + durvalumab is an investigational combination therapy for advanced solid tumors. It consists of AZD8701, a next-generation antisense oligonucleotide (ASO) that selectively targets and depletes forkhead box P3 (FOXP3) mRNA in regulatory T cells (Tregs), thereby reversing their immunosuppressive function within the tumor microenvironment. Durvalumab is a human monoclonal antibody that inhibits programmed death-ligand 1 (PD-L1), blocking its interaction with PD-1 and CD80 to enhance antitumor immune responses. The rationale for combining these agents is to simultaneously relieve Treg-mediated immunosuppression via FOXP3 knockdown and augment immune activation through checkpoint inhibition. This combination has been evaluated in phase I clinical trials in patients with various advanced solid tumors who have progressed on standard therapies, including prior anti-PD-(L)1 treatment[1][2][4][5][7].

Other names

AZD8701 + ImfinziFOXP3 antisense oligonucleotide + durvalumab